<DOC>
<DOCNO>
EP-0000243
</DOCNO>
<TEXT>
<DATE>
19790110
</DATE>
<IPC-CLASSIFICATIONS>
C07D-307/00 C07D-493/00 C07D-493/04 C07H-9/00 C07H-7/02 C07D-307/62 C07H-7/00 C07H-9/04 C07H-7/027 <main>C07D-307/62</main> 
</IPC-CLASSIFICATIONS>
<TITLE>
process for preparing 3,5:4,6- protected derivatives of l- or d- gulonic acid, their use in preparing 2- keto-l- or d- gulonic acid or their esters or l- or d- ascorbic acid, and certain novel 2-nitrato-gulonate intermediates.
</TITLE>
<APPLICANT>
pfizerus<sep>pfizer inc.<sep>pfizer inc.235 east 42nd streetnew york, n.y. 10017us<sep>pfizer inc.<sep>
</APPLICANT>
<INVENTOR>
crawford thomas charles<sep>crawford, thomas charles<sep>crawford, thomas charlesrfd 3, bethel roadnorwich new london, connecticutus<sep>crawford, thomas charles<sep>crawford, thomas charlesrfd 3, bethel roadnorwich new london, connecticutus<sep>
</INVENTOR>
<ABSTRACT>
the invention relates to a process in which a 3,5:4,6-pro­ tected derivative of l- or d-glulonic acid is prepared by con­ tecting l- or d-gulono-1,4-lactone with an aldehyde dialkyl  acetal, or with an aldehyde and an alcohol, in the presence of  an acid having a pka of less than 3.  this protected derivative  may be oxidised and hydrolysed to 2-keto-l- or d-gulonic acid  or ester thereof, which in turn may be hydrolysed to l- or d-­ ascorbic acid.  l-ascorbic acid is of course vitamin c.  the  invention also relates to the novel intermediates produced by  the above processes.  
</ABSTRACT>
</TEXT>
</DOC>
